Home > Rheumatology > EULAR 2022 > Spondyloarthropathies – Novel Developments > Treat-to-target dose reduction effective in spondyloarthritis

Treat-to-target dose reduction effective in spondyloarthritis

Presented By
Dr Celia Michielsens , Sint Maartenskliniek, the Netherlands
Conference
EULAR 2022
Doi
https://doi.org/10.55788/20e9004c
Many patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) need long-term treatment with biologics, which causes considerable costs and might be responsible for an elevated risk of infection. In an open-label, randomised, non-inferiority trial, tapering TNF blockers in patients that achieved remission or at least low disease activity led to a similar proportion of patients still in low disease activity after a year and a 46% lower risk of grade 3 and 4 infections. “What makes our trial relevant? First, we focused on stepwise tapering instead of fixed-dose tapering. Secondly, we used disease-specific targets,” explained Dr Celia Michielsens (Sint Maartenskliniek, the Netherlands). Together with her team, she investigated whether a treat-to-target (T2T) strategy with tapering is non-inferior (with a pre-specified non-inferiority margin of 20%) compared with a T2T strategy without tapering in a randomised, controlled, open-lab...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on